18 results on '"Sharkey R"'
Search Results
2. RADIOIMMUNOTHERAPY OF NON-HODGKINʼS LYMPHOMA WITH AN ANTI-CD22 MONOCLONAL ANTIBODY
3. USING CYTOKINE INTERVENTION TO OVERCOME DOSE-LIMITING, RADIOANTIBODY-INDUCED MYELOTOXICITY
4. TARGETING AND TREATMENT OF MEDULLARY THYROID CANCER WITH I-131-LABELED MURINE ANTI-CEA MONOCLONAL ANTIBODIES
5. ESTIMATES OF RED MARROW DOSE BY SACRAL SCINTIGRAPHY IN NHL PATIENTS WITH DIFFUSE BONE MARROW DISEASE
6. PROBLEMS AND PITFALLS OF 3-STEP AVIDIN-BIOTIN PRETARGETING
7. RADIOIMMUNOTHERAPY OF B-CELL LYMPHOMAS WITH IODINE-131-LABELED LL2 MONOCLONAL ANTIBODY
8. PRECLINICAL AND CLINICAL EVALUATION OF A CDR-GRAFTED (HUMANIZED) ANTI-CARCINOEMBRYONIC ANTIGEN (CEA) MONOCLONAL ANTIBODY (MAb)
9. A PRECLINICAL COMPARISON OF TUMOR THERAPY AND MYELOTOXICITY FOR MU-9 ANTI-CSAp INTACT IgG AND FRAGMENTS LABELED WITH 1–131, Y-90 OR Re-188
10. TREATMENT OF NON-HODGKINʼS LYMPHOMA (NHL) WITH LL2, AN ANTI-CD 22 MONOCLONAL ANTIBODY
11. BIODISTRIBUTION AND PHARMACOKINETIC SCREENING OF THE MoAb PAM4 FOR IMMUNOSCINTIGRAPHY IN PATIENTS WITH PANCREATIC CANCER
12. THREE APPROACHES TO REDUCE RADIOANTI-BODY-INDUCED MYELOSUPPRESSION
13. TARGETING STUDIES IN NON-HODGKINʼS LYMPHOMA PATIENTS WITH A NEW Tc-99M-LABELED MONOCLONAL ANTIBODY IMAGING AGENT
14. TUMOR TARGETING IN PATIENTS WITH A SECOND GENERATION, HIGH-AFFINITY, ANTI- CARCINOEMBRYONIC ANTIGEN (CEA) MURINE MONOCLONAL ANTIBODY
15. DOSE ESCALATION OF RADIOANTIBODY IN A MOUSE MODEL USING RECOMBINANT IL-1 AND GM-CSF INTERVENTION TO REDUCE MYELOSUP-PRESSION
16. THE ANTITUMOR EFFECT AND THE SPECIFIC UPTAKE OF AN ANTI-CEA IMMUNOCONJUGATE (DOX-DEXTRAN-NP-4) IN IN VITRO AND IN VIVO
17. TARGETING AND TREATMENT OF MEDULLARY THYROID CANCER WITH 1-131-LABELED MURINE ANTI-CEA MONOCLONAL ANTIBODIES.
18. A PRECLINICAL COMPARISON TUMOR THERAPY AND MYELO TOXICITY FOR MU-9 ANTI CSAp INTACT IgG AND FRAGMENTS LABELED WITH I-131, Y-90 OR Re-188.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.